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Abstract 
Purpose   Elements in the endocytic process that are determinants of the activities of antifolates delivered by folate 
receptor alpha (FRα) were explored. 
Methods  Antifolate growth inhibition was assessed with a one-day or five day exposure in reduced folate carrier-
null HeLa cell lines that express a high-level of FRα in the presence or absence of the proton-coupled folate 
transporter (PCFT). pH-dependent rates of dissociation from FRα were also determined. 
Results  With a one-day drug exposure which is relevant to the pulse clinical administration of these drugs, FRα 
expression enhanced raltitrexed activity, modestly enhanced ZD9331 activity, but did not significantly augment the 
activity of pemetrexed or lomotrexol. With a five-day drug exposure, FRα-mediated growth inhibition was increased 
for raltitrexed and ZD9331 and emerged for lomotrexol. While the FRα-augmented activity of lomotrexol and 
raltitrexed did not require PCFT, augmentation of ZD9331 activity required the co-expression of PCFT with both 
one-day and five-day exposures.  In contrast, there was no augmentation of pemetrexed activity by FRα under any 
condition. The activities of these agents correlated with their rate of dissociation from the receptor at acidic pH: 
raltitrexed>ZD9331>lomotrexol>pemetrexed consistent with insufficient pemetrexed release from FRα for export 
from the endosomes. 
Conclusions  FRα is unlikely to contribute to the pharmacological activity of antifolates, such as pemetrexed, that 
bind tightly to, and dissociate slowly from, the receptor particularly when the exposure time is brief. While PCFT 
was required for FRα-mediated ZD9931 activity, the activities of the other antifolates was independent of PCFT.
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Introduction  
 
Transport of the water-soluble B9 folate vitamins across the intestinal epithelium and into cells requires folate-
specific transporters. The proton-coupled folate transporter (PCFT-SLC46A1) mediates the intestinal absorption of 
folates and the reduced folate carrier (RFC-SLC19A1) mediates transport into systemic tissues [1-4]. Both are 
facilitative carriers ubiquitously expressed in malignant cells [1,2,4]. Folate receptors (FRs) are expressed on 
epithelial membranes (i.e. apical membranes of the proximal renal tubule and choroid plexus, basolateral membrane 
of retinal pigment epithelial cells) and in epithelial and hematological cancers [5-7]. Since RFC appears to be the 
primary route by which antifolates express their limiting toxicities, antifolates that have a very low affinity for RFC 
are being developed specifically designed for FR-mediated-, and/or PCFT-mediated-, transport. An example of the 
former is the cyclopenta[g]quinazoline-based thymidylate synthase inhibitor, BGC 945 [8]. The pyrrolo[2,3-
d]pyrimidime-based glycinamide ribonucleotide formytransferase (GARFT) inhibitors are agents with a high 
affinity for both FRα and PCFT[2,9-11]. The cytotoxic activity of FR-targeted antifolates requires their 
internalization within endosomes by FR-mediated endocytosis, dissociation from FR upon acidification of the 
endosomes followed by export from endosomes to reach their intracellular targets. Neither the mechanism(s) of 
export, nor the relationship between dissociation from the receptor and export, has been fully clarified. 
 
There is evidence that PCFT is one route of export of folates from endosomes. (i) Subjects with the autosomal 
recessive disorders, hereditary folate malabsorption (OMIM-229050) and cerebral folate transport deficiency 
(OMIM-613068) have markedly impaired transport of folates across the choroid plexus into the cerebrospinal fluid. 
The former is caused by loss-of-function mutations in the PCFT gene while the latter is caused by loss-function-
mutations in the FRα gene [12-17]. This genetic confirmation that both transporters are required to sustain transport 
across this epithelium, neither alone is sufficient, is consistent with a requirement for PCFT for FR function, 
presumably export of folates from the endosome. (ii) PCFT augments FRα-mediated 5-formyltetrahydrofolate (5-
CHO-THF) transport into the cytosol [18]. However, a low level of FRα-mediated 5-CHO-THF transport into the 
cytosol is present in the absence of PCFT and a new class of FR-targeted GARFT inhibitors are active even in the 
absence of PCFT consistent with the presence of another mechanism of endosomal export [9-11,18].  
 
Another class of drugs designed for transport mediated solely by FRs are conjugates in which folic acid is linked 
through a cleavable sulfhydryl bond to a cytotoxic molecule [19]. An example is EC145 (vintafolide), a folic acid-
desacetylvinblastine monohydrazide conjugate now in clinical trials [20,21]. Following endocytosis of this agent, 
the cytotoxic moiety is released from the conjugate when the sulfhydryl bond is reduced following which the 
desacetylvinblastine moiety, which is lipid soluble, diffuses out of the endosome into the cytosol. According to this 
strategy, folic acid need not dissociate from the receptor nor is a specific endosomal export mechanism for the 
cytotoxic component required. A previous study demonstrated that EC0905, an analog of EC145 [22], is highly 
active in an RFC- and PCFT- null HeLa cell line with modestly increased FRα expression consistent with an intact 
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endocytic mechanism. In contrast, these cells are highly resistant to pemetrexed consistent with a failure of 
endocytosed drug to be exported from the endosome and/or released from the receptor [23]. 
 
The objectives of the current study were to better understand the elements of the endocytic process that are the 
determinants of FRα delivery of antifolates, in particular pemetrexed, into tumor cells and the role, if any, of PCFT 
as a contributor to this route of transport . A focus was  to quantify the interaction of antifolates with FRα, in 
particular, the relative rates of dissociation from the receptor as a function of pH. Two HeLa cell lines which express 
very high levels of FRα, but do not express RFC, in the presence or absence of PCFT, were utilized in these studies 
in order to discriminate among binding and transport phenomena intrinsic to endocytic route. 
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Materials and Methods 
 
Cell lines and culture conditions 
Cells utilized for these studies included: R5 cells (derived from wild-type HeLa cells with a genomic deletion of 
RFC but intact PCFT), R5-FR12G (a clonal derivative of R5-cells transfected to a high-level of FRα expression), 
and R1-11-FR2 (a PCFT- null R5 clonal derivative transfected to high-level FRα expression). The origins of these 
cells have been described in detail previously [18,24]. All cells were grown in folate-free RPMI 1640 medium 
supplemented with 10% dialyzed fetal bovine serum, 100 units/mL penicillin, 100 μg/mL streptomycin, and 25 nM 
(6R,S)5-CHO-THF. Hygromycin (0.3 mg/mL) was included in the growth medium to maintain the R1-11-FR2 and 
R5-FR12G cells.  
 
Chemicals  
[3’,5’,7,9-3H]folic acid, [3’,5’,7, 9-3H(N)](6S)5-CHO-THF and generally labeled [3H]pemetrexed were purchased 
from Moravek Biochemicals (Brea, CA). Unlabeled folates/antifolates were obtained from commercial sources: 
pemetrexed from LC laboratories, Woburn, MA; (6R,S) and (6S)5-CHO-THF  from Schircks Laboratories, Jona, 
Switzerland; folic acid  from Sigma, St. Louis, MO; ZD9331 and raltitrexed from AstraZeneca, Cheshire, UK; 
lomotrexol from the Eli Lilly company, Indianapolis, IN; trimetrexate from Warner Lambert, Ann Arbor, MI; and 
EC0905 from Endocyte, West Lafayette, IN. 
 
Growth inhibition by cytotoxic drugs  
Cells were detached with 0.5 mM EDTA in PBS and seeded into 96-well plates (0.1 mL) at a density of 1000 
cells/well for HeLa and 2000 cells/well for the other cell lines. On the second day, 0.1 mL of growth medium 
containing a range of drug concentrations in the presence or absence of folic acid was added. For one-day drug 
exposures, the medium containing drug was removed after 24 hrs. The cells were then washed rapidly once with 0.1 
mL folate-free RPMI medium following which 0.2 mL of this medium containing 25 nM (6R,S)5-CHO-THF was 
added, and the cells were grown for four more days. Otherwise cells were grown continuously in their respective 
media for five days (five-day exposure). Cell growth was analyzed by sulforhodamine B staining.  
 
Buffers 
Following buffers were used: HBS (20mM HEPES, 5mM dextrose, 140mM NaCl, 5mM KCl, 2mM MgCl2) with 
pH adjusted to 7.4 and 7.0. MBS (20mM MES, 5mM dextrose, 140mM NaCl, 5mM KCl, 2mM MgCl2) with pH 
adjusted to 6.5, 6.0, 5.5 and 5.0. Acid buffer (10mM sodium acetate, 150mM NaCl, adjusted to pH 3.5 with acetic 
acid) was used to dissociate folates/antifolates from FRα. 
 
Folic acid surface binding and its inhibition by other antifolates  
Cells grown in 12-well plates to near confluence were washed consecutively with 2 mL ice-cold HBS (pH7.4), 
acidic buffer (pH 3.5), HBS (pH 7.4), each for 5 min. Cells were then incubated with 0.2, 0.5 or 1.0 µM[3H]folic 
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acid alone, or with a mixture of 0.5 µM [3H]folic acid and unlabeled folates or antifolates, in ice-cold HBS (pH 7.4) 
for 20 min. After three washes with ice-cold HBS (pH 7.4, 2 mL, 5 min), surface-bound [3H]folic acid was released 
by incubation with 0.5mL of ice-cold acid buffer (pH 3.5) for 5 min. Tritium in the acid buffer was quantified on a 
liquid scintillation spectrometer and normalized to protein determined with the BCA Protein Assay (Pierce, 
Rockford, IL) after cells were dissolved in 0.5 mL of 0.2 M NaOH.  
 
pH-dependent antifolate/folate dissociation from FRα  
Three different assays were utilized: (i) Direct measurement of radiolabeled substrates at 0oC—Cells in 12-well 
plates were washed (2 mL, 5min) consecutively with ice-cold HBS (pH 7.4), acid buffer (pH 3.5), and HBS (pH 7.4) 
to remove unlabeled 5-CHO-THF from the medium bound to FRα. The cells were then incubated with 1 mL of 0.5 
µM [3H]folic acid, [3H](6S)5-CHO-THF or  [3H]pemetrexed in HBS (pH 7.4) for 20 min on ice to saturate surface 
FRα. The unbound tritiated compounds were removed by washing with ice-cold HBS (pH 7.4) three times (2 mL, 
1min). The cells were then incubated with 2 mL of buffers at a pH of from 5.0 to 7.4 for 5 min on ice following 
which tritium that remained bound to FRα was released with a 5 min incubation with 0.5 mL acid buffer (pH 3.5) 
and quantified as described above. The greater the quantity of tritium retrieved, the slower the rate of dissociation 
from FRα. (ii) Indirect measurement of non-radiolabeled substrates at 0oC-- Cells in 12-well plates were washed 
(2 mL, 5min) consecutively with ice-cold HBS (pH 7.4), acid buffer (pH 3.5), and HBS (pH 7.4) to remove 5-CHO-
THF from the medium bound to FRα at the cell surface. The cells were then incubated for 20 min with 1mL ice-cold 
HBS (pH 7.4) containing 2 µM of non-labelled ZD9331, raltitrexed, lomotrexol or pemetrexed to saturate FRα. 
Following this, the cells were washed once with 2mL ice-cold HBS (pH 7.4) for 1 min and exposed to 2 mL of ice-
cold buffers at different pH’s for 5 min to release the FRα-bound antifolate. After a 1 min wash with 2 mL HBS (pH 
7.4) cells were incubated for 1 min with 0.5 µM [3H](6S)5-CHO-THF in HBS (1mL, pH 7.4) to reload the receptors. 
After three 1 min washes with 2 mL ice-cold HBS (pH 7.4), the tritium was released from the cell surface with a 5 
min incubation with 0.5 mL acidic buffer (pH 3.5) and quantified. In this experimental design, the greater the 
amount of tritium released the more rapid the rate of dissociation of antifolate from the receptor.  As a control, cells 
were incubated with HBS (pH7.4) in the absence of the antifolates. (iii) Indirect measurement of non-
radiolabeled substrates at 37o. The procedure was  the same as (ii) except that the dissociation step was performed 
with a 10 min incubation at 37o in pre-warmed buffers (1mL, pH 5.0 to 7.4) containing 2 µM of antifolate. 
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Results 
 
Characterization of cell lines employed in these studies 
The HeLa cell line and its three variants, developed in this laboratory, were used in the current study to assess the 
contribution of FRα-mediated transport to antifolate activities and the role of PCFT in this process.  These were: (1) 
HeLa wild-type cells (RFC+PCFT+); (2) R5 cells (RFC-PCFT+); (3) R5-FR12G cells (RFC-PCFT+FR+++++); (4) R1-
11-FR2 cells (RFC-PCFT-FR+++++). Hence, only wild-type HeLa cells express RFC. Cells were grown in folate-free 
medium supplemented with 25 nM (6R,S)5-CHO-THF. Folic acid was not utilized as a folate growth source to 
allow determination of FRα-mediated antifolate growth inhibition. R1-11 (RFC-PCFT-FR-) cells do not grow at this 
concentration of (6R,S)5-CHO-THF and, thus, were not included in the current study [25,26]. 
FRα surface expression was determined using [3H]folic acid concentrations (0,2 , 0.5 and 1 µM) sufficiently high to 
ensure that the folic acid content in the buffer was far in excess of that required to saturate surface FRα sites (Fig. 
1a). The FRα level in HeLa cells was greater than in R5 cells. Levels in R1-11-FR2 and R5-FR12G cells were 
markedly increased, identical, and constant over the concentration range, consistent with saturation of the receptors. 
This FRα level in R1-11-FR2 and R5-FR12G cells was ~3 times greater than that of KB cells [7]. 
Competitive binding of antifolates to FRα in FR1-11-FR2 and R5-FR12G cells  
Four antifolates (ZD9331, lomotrexol, raltitrexed and pemetrexed) were studied; all have been reported to have 
excellent, though variable, affinities for FRα [27,28]. As indicated in Figs. 1b and 1 c, the pattern and extent to 
which these antifolates competed with [3H]folic acid for binding to FRα were nearly identical in the R1-11-FR2 and 
R5-FR12G cells. The potency of inhibition, reflective of affinity of antifolates for FRα was in following order: 
lomotrexol > ZD9331, pemetrexed >raltitrexed.  The competitive potency of lomotrexol for FRα was comparable to 
that of folic acid; the potency of (6S)-5-CHO-THF, the folate source in the growth medium, was between that of 
pemetrexed and raltitrexed. 
Growth inhibition by trimetrexate-an indication of the cell folate pool 
Growth inhibition by trimetrexate was assessed in the four cell lines with a five-day drug exposure. This antifolate  
is highly sensitive to the intracellular folate level which generally affects the activity of antifolates. Among the four 
antifolates used in the current study, lomotrexol is the most sensitive to cell folate levels, followed by pemetrexed 
and raltitrexed. ZD9331 is the least sensitive to intracellular folates since its structure precludes formation of 
polyglutamate derivatives, a process suppressed by intracellular folates [29,30] . Trimetrexate is a relatively weak 
dihydrofolate reductase inhibitor that enters cells by passive diffusion and does not form polyglutamate derivatives. 
Increased levels of intracellular folates enhance competition with trimetrexate for binding to dihydrofolate reductase 
and decrease the activity of this agent [29]. As indicated in Table 1, trimetrexate activity was markedly increased in 
R5 versus wild-type HeLa cells consistent with a contraction in the folate pool that accompanies the loss of RFC, as 
previously reported. This contributes to the preservation of pemetrexed activity (by augmenting its polyglutamation) 
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in these cells [31,32]. Trimetrexate activity was markedly decreased (35-fold) in R5-FR12G versus R5 cells, 
consistent with a marked FRα –mediated increase in the cellular folate pool that appeared to be, in part, PCFT-
dependent since trimetrexate activity was 10-fold weaker in the R5-FR12G as compared to the R1-11 FR2 cells. 
Trimetrexate activity was also determined when 200 nM folic acid was added to the growth media during the assay, 
a common approach to block FR-mediated uptake.  Addition of 200 nM folic acid did not alter trimetrexate activity 
in HeLa and R5 cells. On the other hand, folic acid at this concentration markedly (~ 8 fold) increased the activities 
of trimetrexate in both FRα-expressing cells, consistent with its potent inhibition of FRα-mediated (6S)5-CHO-THF 
transport and consequent folate depletion.  
Cell growth inhibition after a one-day exposure to EC0905 or antifolates  
Growth inhibition by EC0905 (a folic acid-desoxyvinblastine conjugate), ZD9331, raltitrexed, pemetrexed and 
lomotrexol after a one-day exposure was assessed and their IC50 values presented in Table I.  The EC0905 IC50’s in 
HeLa and R5 cells were in the 0.6-0.9 µM range and were barely affected by the presence of folic acid. Hence, the 
level of FRα expression in these cell lines was insufficient to augment the activity of this agent.  The EC0905 IC50 
was less than 1 nM in R5-FR12G and R1-11-FR2 cells and the addition of folic acid completely abolished its 
activity. Hence, FRα-mediated endocytosis was intact in both R5-FR12G and R1-11-FR2 cells allowing assessment 
of FRα-dependent activities of the antifolates. 
The IC50 for ZD9331 in HeLa and R5 cells was >20 µM but was decreased by an order of magnitude to 0.9 µM in 
R5-FR12G cells; the addition of 200 nM folic acid increased the IC50 by >6.7-fold. In contrast, the IC50 was >20 µM 
for ZD9331 in R1-11-FR2 cells and was unaffected by folic acid. Hence, ZD9331 growth inhibition mediated by 
FRα, albeit weak, required the co-expression of PCFT. 
Raltitrexed was much more active in HeLa cells than in R5 cells that express only PCFT, consistent with its high 
affinity for RFC and very low affinity for PCFT at neutral pH [31]. Raltitrexed activity was increased in R5-FR12G 
cells relative to R5 but its activity was ten-fold greater in the R1-11-FR2 cells that lack PCFT. In both cases there 
was a marked fall to a comparable level of activity in the presence of 200 nM folic acid. Hence, there was a modest 
increase in raltitrexed activity in the cells that express PCFT and FRα but, paradoxically, its activity was much 
greater when PCFT was absent.  
Pemetrexed had comparable activities in HeLa and R5 cells; its activity was sustained in the latter cells due in part 
to its high affinity for PCFT, as reported previously, and the concurrent contraction of the folate pools which 
augments its polyglutamation as indicated by the high sensitivity of R5 cells to trimetrexate [24,31]. Pemetrexed 
activity was substantially lower in both cell lines that overexpress FRα with only a small decrease in activity with 
the addition of folic acid. A similar pattern was observed for lomotrexol. Hence, pemetrexed and lomotrexol 
activities were low in cells with high expression of FRα irrespective of the co-expression of PCFT.  
Cell growth inhibition after a five-day exposure to EC0905 or antifolates  
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A five-day exposure markedly prolongs the duration over which drug can enter the cells and synthesize the 
polyglutamate derivatives of pemetrexed, raltitrexed, and lomotrexol. The EC0905 IC50’s for the R5-FR12G and R1-
11-FR2 were essentially the same as obtained with the one-day exposure indicating that the short exposure was 
sufficient to achieve the full activity of the conjugate in these cells at this level of FRα expression.  However, the 
activities of all the antifolates were substantially increased with the longer duration of exposure. 
For ZD9331, the IC50’s were decreased in all the cell lines as compared to the one-day exposure. However, there 
was a marked decrease in the IC50 in R5-FR12G cells to 1.4% that of HeLa and R5 cells and this activity was 
essentially abolished by the presence of folic acid increasing the IC50 by a factor of 500. In contrast, ZD9331 was 
not active in R1-11-FR2 cells, similar to what was observed with the one-day exposure. Hence, PCFT was 
absolutely required for FRα-mediated ZD9331 growth inhibition regardless of the interval of drug exposure. The 
pattern of raltitrexed activity with a five-day exposure was similar to that of the one day exposure in all cell lines 
except that raltitrexed was more active with the longer exposure; activity was markedly suppressed by folic acid 
despite the contraction of folate pools that occurs under these conditions. Raltitrexed activity was modestly 
increased in the R1-11-FR2 cells in the absence of PCFT. Hence, FRα -mediated growth inhibition by raltitrexed did 
not require co-expression of PCFT. The increased activity in the absence of PCFT correlated with the contraction of 
the folate pools in these cells as reflected by the increased trimetrexate activity, as indicated above. 
Pemetrexed growth inhibition was modestly increased in all cell lines as compared to the one-day exposure; 
however, there was no impact at all of PCFT in cells that express high levels of FRα and there was only a small 
decrease in activity upon the addition of folic acid. Hence, the data suggests that FRα did not contribute to the 
activity of this drug in the presence or absence of PCFT.  In contrast, growth inhibition by lomotrexol was markedly 
increased in both R1-11-FR2 and R5-FR12G cells, as compared to the one-day exposure, and there was a substantial 
decrease in activity with the addition of folic acid. However, the presence of PCFT in R5-FR12G cells did not 
augment the activity of this agent as compared to PCFT-null R1-11-FR2 cells.  
The pH-dependent dissociation of folates and antifolate substrates from FRα  
In FRα-mediated endocytosis, the endosomal pH must be decreased for the dissociation of substrate from receptor to 
occur before the folate can be exported into the cytosol. Folic acid is bound so tightly to FRα that it dissociates from 
the receptor very slowly; because of this it has been considered to be a very poor substrate for FRα-mediated 
transport  [5]. Dissociation was assessed for tritiated folic acid, (6S)5-CHO-THF and pemetrexed at 0oC. Surface 
FRα was first saturated with the tritiated compounds; the cells were then washed with 0oC buffer, incubated with 
ice-cold folate-free buffers at different pHs and tritium remaining bound to the cell surface was quantified. As 
indicated in Fig. 2a, most folic acid and pemetrexed remained bound to the cells even when the pH was decreased to 
5.0. The slight decrease in bound pemetrexed at low pH was not significant (P=0.20 and 0.48 at pH 5.0 and pH 5.5, 
respectively) as compared to pH 7.4. In contrast, (6S)5-CHO-THF dissociation started at pH 6 and only 30% and 
10% remained bound to the cells at pH 5.5 and 5, respectively.  
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Since raltitrexed, ZD9331 and lomotrexol in their tritiated forms were not available, an indirect measurement of 
binding to FRα at 0oC was utilized.  FRα at the cell surface was first saturated with these unlabeled antifolates; the 
cells were washed with 0oC buffer then incubated with ice-cold buffers at different pHs to allow dissociation. The 
cells were then washed with buffer at neutral pH, and the unoccupied receptors quantified with [3H](6S)5-CHO-
THF.  The time-course of dissociation of raltirexed at pH 7.4 is illustrated in Fig. 2b. It can be seen that a brief 
incubation (<2 min) with [3H](6S)5-CHO-THF detected a major portion of unoccupied receptors in the control cells 
but only ~10% of the bound raltitrexed was replaced. Even a 20 min-incubation with [3H](6S)5-CHO-THF resulted 
in dissociation of only 60% of the bound raltitrexed indicating that the dissociation process under these conditions 
(pH 7.4, 0oC) was slow. 
Fig. 2c compares the pH-dependent dissociation of ZD9331, raltitrexed, lomotrexol and pemetrexed at 0oC using the 
indirect measurement. As the pH was decreased, the extent of dissociation for all the antifolates was relatively 
unchanged between pH 7.4 and 6.0. However, at pH 5.5, raltitrexed dissociation was complete and ZD9331 was 
75% dissociated. At pH 5.0, ZD9331 dissociation was complete. Lometrexol dissociation was detected at pH 5.5 but 
complete dissociation required pH 5.0. In contrast, pemetrexed dissociation at pH 5.5 was not different from the 
dissociation at higher pHs (P>0.05).  Even at pH 5.0 only 45% of the pemetrexed had dissociated from the cell 
surface. The high background dissociation at neutral pH for raltitrexed, and to a lesser extent pemetrexed, was due to 
the wash procedure and the replacement of unlabeled substrates with [3H](6S)-5-CHO-THF.  
Using a similar approach, the percentage of antifolate substrates dissociated from FRα at the cell surface was 
assessed after surface receptors were first saturated with 2 µM folates/antifolates at 0oC. The cells were then 
exposed to a spectrum of buffers at different pH’s, this time at 37oC for 10 min, each of which contained 2 µM of 
the same substrate allowing dissociation to approach an equilibrium between the bound and free antifolates. After a 
rapid wash, cells were incubated with [3H](6S)5-CHO-THF for 1 min on ice to assess the amount of unoccupied 
receptors. As indicated in Fig. 3, folic acid did not dissociate from receptors on the cell surface, at all, even at pH 5.0 
under these conditions. There was marked dissociation of raltitrexed below pH 6.0 reaching ~80% at pH 5.0. 
Dissociation of ZD9331 began at pH 5.5 and reached 50% at pH 5.0. Lomotrexol did not dissociate until the pH 
reached 5.5. Pemetrexed dissociation from the receptors was minimal even at pH 5.0 under these conditions.   
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Discussion 
The objectives of this study were to better understand the elements of the endocytic process that are the 
determinants of FRα-mediated delivery of antifolates into tumor cells and the role that PCFT might play in this 
process. The pair of cell lines, R1-11-FR2 and R5-FR12G, offered unique models for this investigation. (i) Both lack 
RFC and have high, comparable expression of FRα. (ii) R5-FR12G expresses PCFT but R1-11-FR2 does not. (iii) 
FRα-mediated endocytosis was functional in both cell lines since both were highly sensitive to EC0905. The data 
indicate that (i) the requirement for PCFT in FRα-mediated antifolate growth inhibition in these cell lines is 
substrate-specific, (ii) the rate of dissociation of antifolate from the receptor at acidic pH, is a critical determinant of 
the activity of these agents, and (iii) the impact of FRα expression on antifolate activities is modulated by concurrent 
alterations in the levels of cellular folates that suppress the polyglutamation of antifolates within cells.  
FRα-mediated antifolate activities were very limited when the interval of drug exposure was one-day 
except for raltitrexed. Interestingly, raltitrexed has the lowest affinity for FRα at neutral pH evaluated (Fig. 1b and 
1c), and the highest propensity to dissociate from FRα at neutral or lower pHs, among the four antifolates studied 
(Figs. 2c and 3). Since this short-term exposure better simulates the conditions in which these drugs are given as 
pulse infusions followed by their rapid renal and hepatic clearance, these data indicate that antifolates with very high 
affinity for FRα should be poor substrates for delivery by this transporter in the clinical setting. This is due to a low 
level of dissociation of antifolate from the receptor in the endosomes and thus a slow delivery of drug into the 
cytosol. Hence, what is required is for the antifolate to have high enough affinity to assure sufficient binding to FRα 
after administration of the drug but not so high an affinity that dissociation from FRα at endosome pH is too slow to 
result in antitumor activity. Another element in FRα-mediated antifolate activity is receptor-mediated uptake of 5-
methyltetrahydrofolate (the physiological folate) that increases the level of intracellular folates and reduces the 
efficacy of antifolates that require polyglutamation for their activity [29,33]. 
The five day exposure is much less clinically relevant but provides additional mechanistic information. 
Under these conditions, FRα-mediated raltitrexed activity was further enhanced and lomotrexol activity emerged – 
both activities were PCFT-independent. In contrast, even with a one-day exposure the activity of ZD9331 was 
augmented by FRα and this was markedly increased at five days; however, this only occurred in cells that expressed 
PCFT and was blocked by folic acid. Hence, while PCFT was absolutely required for FRα-mediated ZD9331 
activity this was not the case for the other antifolates, observations that suggest another mechanism by which these 
antifolates exit endosomes in these cells. This is also relevant for a new generation of GARFT inhibitors with high 
affinity for FRα and very low affinity for RFC that are active in tumor cells that lack PCFT [9-11,18].  The best 
explanation for these findings is that ZD9331 export from endosomes is PCFT-dependent, export of the other 
antifolates is not, at least in these cells. 
At the very low concentration of folic acid employed in these studies (200 nM) to block FRα function 
neither RFC- or PCFT-mediated transport of (6S)5-CHO-THF is suppressed.  The sole impact of the added folic 
acid reflected inhibition of FRα-mediated endocytosis. Hence, the marked inhibition of raltitexed activity by the 
12 
 
addition of folic acid confirmed the critical role of receptor-mediated endocytosis as a determinant of the activity of 
this agent.  This was also observed for the longer exposure to lomotrexol. The greater activities mediated by FRα for 
the two agents in the absence of PCFT also correlated with a decrease in the folate pool as reflected by the increased 
sensitivity to trimetrexate. Under both conditions, a decrease in activity in the presence of folic acid occurred despite 
a marked decrease in intracellular folates indicating that increased polyglutamylation due to the reduced intracellular 
folate level was insufficient to compensate the loss of FRα-mediated drug transport.  
Pemetrexed is standard-of-care in the treatment of advanced mesothelioma and non-squamous non-small-cell lung 
cancer [34-36]. FRα is expressed in these tumors [37-39]; however, it has been unclear as to whether this contributes 
to activity of this drug. FRα-mediated pemetrexed activity was not observed with either a one- or five- day exposure 
to the drug in the current study. Nor was FRα-mediated pemetrexed activity significantly influenced by the presence 
or absence of PCFT. An analysis of the pH-dependent dissociation of the antifolates established that the failure of 
FRα to augment the activity of pemetrexed was due to the failure of this drug to dissociate from the receptor at pH 
relevant to what occurs in endosomes during their cycling.  The data suggests that competitive binding analyses at 
neutral pH do not provide the critical information regarding FR-delivery of antifolates since pemetrexed’s binding 
properties in this assay were comparable to that of ZD9331 and weaker than that of folic acid and lomotrexol.  
Rather, an analysis of its dissociation from FRα as a function of pH was much more informative and correlated with 
the impact of FRα on the activity of pemetrexed in intact HeLa cells. In this case, dissociation was slowest  at pH 
5.0, at both 0oC and 37 oC, although the relative affinity of pemetrexed for FRα at 37 oC was far less than at 0oC 
[40]. Hence, for pemetrexed, little or no free drug apparently becomes available to exit the endosomes by PCFT or 
any other mechanism(s) even with prolong exposure to the drug. Hence, the data indicate that folate receptor-
mediated endocytosis does not contribute to the pharmacological activity of pemetrexed in these HeLa cell lines 
even under conditions in which this protein is highly expressed and the endocytic mechanism is intact and mediates 
the activities of other antifolates. 
 
 
Acknowledgments 
This work was supported by grants from the National Institutes of Health [CA-82621 and CA-013330]. 
 
Conflict of interest     No conflict to disclose 
  
13 
 
References 
 
 1.  Zhao R, Diop-Bove N, Visentin M and Goldman I D (2011) Mechanisms of Membrane Transport of Folates 
into Cells and Across Epithelia. Annu Rev Nutr 31:177-201. 
 2.  Desmoulin SK, Hou Z, Gangjee A and Matherly L H (2012) The Human Proton-Coupled Folate Transporter: 
Biology and Therapeutic Applications to Cancer. Cancer Biol Ther 13:1355-1373. 
 3.  Visentin M, Diop-Bove N, Zhao R and Goldman I D (2014) The Intestinal Absorption of Folates. Annu Rev 
Physiol 76:251-274. 
 4.  Zhao R and Goldman I D (2013) Folate and Thiamine Transporters Mediated by Facilitative Carriers 
(SLC19A1-3 and SLC46A1) and Folate Receptors. Mol Aspects Med 34:373-385. 
 5.  Kamen BA and Smith A K (2004) A Review of Folate Receptor Alpha Cycling and 5-Methyltetrahydrofolate 
Accumulation With an Emphasis on Cell Models in Vitro. Adv Drug Deliv Rev 56:1085-1097. 
 6.  Elnakat H and Ratnam M (2004) Distribution, Functionality and Gene Regulation of Folate Receptor 
Isoforms: Implications in Targeted Therapy. Adv Drug Deliv Rev 56:1067-1084. 
 7.  Parker N, Turk M J, Westrick E, Lewis J D, Low P S and Leamon C P (2005) Folate Receptor Expression in 
Carcinomas and Normal Tissues Determined by a Quantitative Radioligand Binding Assay. Anal Biochem 
338:284-293. 
 8.  Gibbs DD, Theti D S, Wood N, Green M, Raynaud F, Valenti M, Forster M D, Mitchell F, Bavetsias V, 
Henderson E and Jackman A L (2005) BGC 945, a Novel Tumor-Selective Thymidylate Synthase Inhibitor 
Targeted to Alpha-Folate Receptor-Overexpressing Tumors. Cancer Res 65:11721-11728. 
 9.  Wang L, Cherian C, Desmoulin S K, Polin L, Deng Y, Wu J, Hou Z, White K, Kushner J, Matherly L H and 
Gangjee A (2010) Synthesis and Antitumor Activity of a Novel Series of 6-Substituted Pyrrolo[2,3-
d]Pyrimidine Thienoyl Antifolate Inhibitors of Purine Biosynthesis With Selectivity for High Affinity Folate 
Receptors and the Proton-Coupled Folate Transporter Over the Reduced Folate Carrier for Cellular Entry. J 
Med Chem 53:1306-1318. 
 10.  Wang L, Desmoulin S K, Cherian C, Polin L, White K, Kushner J, Fulterer A, Chang M H, Mitchell-Ryan S, 
Stout M, Romero M F, Hou Z, Matherly L H and Gangjee A (2011) Synthesis, Biological, and Antitumor 
Activity of a Highly Potent 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolate Inhibitor With 
Proton-Coupled Folate Transporter and Folate Receptor Selectivity Over the Reduced Folate Carrier That 
Inhibits Beta-Glycinamide Ribonucleotide Formyltransferase. J Med Chem 54:7150-7164. 
 11.  Wang Y, Cherian C, Orr S, Mitchell-Ryan S, Hou Z, Raghavan S, Matherly L H and Gangjee A (2013) 
Tumor-Targeting With Novel Non-Benzoyl 6-Substituted Straight Chain Pyrrolo[2,3-d]Pyrimidine 
Antifolates Via Cellular Uptake by Folate Receptor Alpha and Inhibition of De Novo Purine Nucleotide 
Biosynthesis. J Med Chem 56:8684-8695. 
 12.  Qiu A, Jansen M, Sakaris A, Min S H, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas M H and 
Goldman I D (2006) Identification of an Intestinal Folate Transporter and the Molecular Basis for Hereditary 
Folate Malabsorption. Cell 127:917-928. 
 13.  Zhao R, Min S H, Qiu A, Sakaris A, Goldberg G L, Sandoval C, Malatack J J, Rosenblatt D S and Goldman I 
D (2007) The Spectrum of Mutations in the PCFT Gene, Coding for an Intestinal Folate Transporter, That 
Are the Basis for Hereditary Folate Malabsorption. Blood 110:1147-1152. 
14 
 
 14.  Diop-Bove N, Kronn D and Goldman I D (2011) Hereditary Folate Malabsorption, in GeneReviews [Internet] 
(Pagon RA, Bird TD, Dolan CR and Stephens K eds) Unverisity of Washington, Seattle, Seattle (WA). 
 15.  Cario H, Bode H, Debatin K M, Opladen T and Schwarz K (2009) Congenital Null Mutations of the FOLR1 
Gene: a Progressive Neurologic Disease and Its Treatment. Neurology 73:2127-2129. 
 16.  Steinfeld R, Grapp M, Kraetzner R, Dreha-Kulaczewski S, Helms G, Dechent P, Wevers R, Grosso S and 
Gartner J (2009) Folate Receptor Alpha Defect Causes Cerebral Folate Transport Deficiency: a Treatable 
Neurodegenerative Disorder Associated With Disturbed Myelin Metabolism. Am J Hum Genet 85:354-363. 
 17.  Grapp M, Just I A, Linnankivi T, Wolf P, Lucke T, Hausler M, Gartner J and Steinfeld R (2012) Molecular 
Characterization of Folate Receptor 1 Mutations Delineates Cerebral Folate Transport Deficiency. Brain2022-
2031. 
 18.  Zhao R, Min S H, Wang Y, Campanella E, Low P S and Goldman I D (2009) A Role for the Proton-Coupled 
Folate Transporter (PCFT - SLC46A1) in Folate Receptor-Mediated Endocytosis. J Biol Chem 284:4267-
4274. 
 19.  Xia W and Low P S (2010) Folate-Targeted Therapies for Cancer. J Med Chem 53:6811-6824. 
 20.  Vlahov IR, Santhapuram H K, Kleindl P J, Howard S J, Stanford K M and Leamon C P (2006) Design and 
Regioselective Synthesis of a New Generation of Targeted Chemotherapeutics. Part 1: EC145, a Folic Acid 
Conjugate of Desacetylvinblastine Monohydrazide. Bioorg Med Chem Lett 16:5093-5096. 
 21.  Naumann RW, Coleman R L, Burger R A, Sausville E A, Kutarska E, Ghamande S A, Gabrail N Y, 
Depasquale S E, Nowara E, Gilbert L, Gersh R H, Teneriello M G, Harb W A, Konstantinopoulos P A, 
Penson R T, Symanowski J T, Lovejoy C D, Leamon C P, Morgenstern D E and Messmann R A (2013) 
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal 
Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer. 
J Clin Oncol 31:4400-4406. 
 22.  Dhawan D, Ramos-Vara J A, Naughton J F, Cheng L, Low P S, Rothenbuhler R, Leamon C P, Parker N, 
Klein P J, Vlahov I R, Reddy J A, Koch M, Murphy L, Fourez L M, Stewart J C and Knapp D W (2013) 
Targeting Folate Receptors to Treat Invasive Urinary Bladder Cancer. Cancer Res 73:875-884. 
 23.  Zhao R, Diop-Bove N and Goldman I D (2014) Enhanced Receptor-Mediated Endocytosis and Cytotoxicity 
of a Folic Acid-Desacetylvinblastine Monohydrazide Conjugate in a Pemetrexed-Resistant Cell Line Lacking 
Folate-Specific Facilitative Carriers but With Increased Folate Receptor Expression. Mol Pharmacol 85:310-
321. 
 24.  Zhao R, Gao F, Hanscom M and Goldman I D (2004) A Prominent Low-PH Methotrexate Transport Activity 
in Human Solid Tumor Cells: Contribution to the Preservation of Methotrexate Pharmacological Activity in 
HeLa Cells Lacking the Reduced Folate Carrier. Clin Cancer Res 10:718-727. 
 25.  Zhao R, Chattopadhyay S, Hanscom M and Goldman I D (2004) Antifolate Resistance in a HeLa Cell Line 
Associated With Impaired Transport Independent of the Reduced Folate Carrier. Clin Cancer Res 10:8735-
8742. 
 26.  Diop-Bove NK, Wu J, Zhao R, Locker J and Goldman I D (2009) Hypermethylation of the Human Proton-
Coupled Folate Transporter (SLC46A1) Minimal Transcriptional Regulatory Region in an Antifolate-
Resistant HeLa Cell Line. Molecular Cancer Therapeutics 8:2424-2431. 
 27.  Westerhof GR, Schornagel J H, Kathmann I, Jackman A L, Rosowsky A, Forsch R A, Hynes J B, Boyle F T, 
Peters G J, Pinedo H M and Jansen G (1995) Carrier- and Receptor-Mediated Transport of Folate Antagonists 
15 
 
Targeting Folate-Dependent Enzymes:  Correlates of Molecular- Structure and Biological Activity. Mol 
Pharmacol 48:459-471. 
 28.  Theti DS and Jackman A L (2004) The Role of Alpha-Folate Receptor-Mediated Transport in the Antitumor 
Activity of Antifolate Drugs. Clin Cancer Res 10:1080-1089. 
 29.  Zhao R, Gao F and Goldman I D (2001) Marked Suppression of the Activity of Some, but Not All, Antifolate 
Compounds by Augmentation of Folate Cofactor Pools Within Tumor Cells. Biochem Pharmacol 61:857-
865. 
 30.  Jackman AL, Kimbell R, Aherne G W, Brunton L, Jansen G, Stephens T C, Smith M N, Wardleworth J M 
and Boyle F T (1997) Cellular Pharmacology and in Vivo Activity of a New Anticancer Agent, ZD9331: a 
Water-Soluble, Nonpolyglutamatable, Quinazoline-Based Inhibitor of Thymidylate Synthase. Clin Cancer 
Res 3:911-921. 
 31.  Zhao R, Hanscom M, Chattopadhyay S and Goldman I D (2004) Selective Preservation of Pemetrexed 
Pharmacological Activity in HeLa Cells Lacking the Reduced Folate Carrier; Association With the Presence 
of a Secondary Transport Pathway. Cancer Res 64:3313-3319. 
 32.  Chattopadhyay S, Zhao R, Krupenko S A, Krupenko N and Goldman I D (2006) The Inverse Relationship 
Between Reduced Folate Carrier Function and Pemetrexed Activity in a Human Colon Cancer Cell Line. Mol 
Cancer Ther 5:438-449. 
 33.  Andreassi JL and Moran R G (2002) Mouse Folylpoly-Gamma-Glutamate Synthetase Isoforms Respond 
Differently to Feedback Inhibition by Folylpolyglutamate Cofactors. Biochemistry 41:226-235. 
 34.  Vogelzang NJ, Rusthoven J J, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri 
S, Manegold C, Niyikiza C and Paoletti P (2003) Phase III Study of Pemetrexed in Combination With 
Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. J Clin Oncol 21:2636-
2644. 
 35.  Hanna N, Shepherd F A, Fossella F V, Pereira J R, De Marinis F, Von Pawel J, Gatzemeier U, Tsao T C, 
Pless M, Muller T, Lim H L, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, 
Einhorn L and Bunn P A, Jr. (2004) Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients 
With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy. J Clin Oncol 22:1589-1597. 
 36.  Scagliotti GV, Parikh P, Von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier 
U, Digumarti R, Zukin M, Lee J S, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, De Marinis F, Simms 
L, Sugarman K P and Gandara D (2008) Phase III Study Comparing Cisplatin Plus Gemcitabine With 
Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung 
Cancer. J Clin Oncol 26:3543-3551. 
 37.  Bueno R, Appasani K, Mercer H, Lester S and Sugarbaker D (2001) The Alpha Folate Receptor Is Highly 
Activated in Malignant Pleural Mesothelioma. J Thorac Cardiovasc Surg 121:225-233. 
 38.  Christoph DC, Asuncion B R, Hassan B, Tran C, Maltzman J D, O'Shannessy D J, Wynes M W, Gauler T C, 
Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt W E and Hirsch F R (2013) Significance of Folate 
Receptor Alpha and Thymidylate Synthase Protein Expression in Patients With Non-Small-Cell Lung Cancer 
Treated With Pemetrexed. J Thorac Oncol 8:19-30. 
 39.  Nunez MI, Behrens C, Woods D M, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee J J, Franklin 
W, Stewart D J and Wistuba I I (2012) High Expression of Folate Receptor Alpha in Lung Cancer Correlates 
With Adenocarcinoma Histology and EGFR [Corrected] Mutation. J Thorac Oncol 7:833-840. 
16 
 
 40.  Leamon CP, You F, Santhapuram H K, Fan M and Vlahov I R (2009) Properties Influencing the Relative 
Binding Affinity of Pteroate Derivatives and Drug Conjugates Thereof to the Folate Receptor. Pharm Res 
26:1315-1323. 
 
 
  
17 
 
 
Figure legends 
Figure 1. Folic acid surface binding capacity in the cell lines studied and the effect of unlabeled folates/antifolates 
on binding of tritiated folic acid to FRα in R1-11-FR2 and R5-FR12G cells. (1a) Cells were incubated with 200, 500 
and 1000 nM [3H]folic acid for 20 min on ice and then washed with neutral buffer. Tritium on the cells surface was 
released by acidic buffer and quantified. (1b and 1c) Competitive binding with [3H]folic acid in R1-11-FR2 (b) and 
R5-FR12G cells (c).  Three different concentrations of each unlabeled folate or antifolate were employed during 
incubation with 500 nM [3H] folic acid following which tritium released from the cell surface was measured. Data in 
all panels are the mean ±S.E.M. from three independent experiments. 
Figure 2. pH-dependent dissociation of folate/antifolate substrates from the surface of R1-11-FR2 cells at 0oC. (a): 
Dissociation of tritiated substrates from FRα as a function of pH at 0oC. Cells were incubated with 0.5 µM [3H]folic 
acid, [3H](6S)5-CHO-THF or [3H]pemetrexed for 20 min to saturate FRα on the cell surface. The cells were then 
washed with 0oC neutral buffer, incubated with ice-cold folate-free buffers at a spectrum of pHs for 5 min, following 
which tritium that remained bound to the cell surface was released by acid buffer and quantified. (b): Time-course 
of dissociation of raltitrexed at 0oC at pH 7.4. Cells were incubated in buffer alone (control) or with 2 µM raltitrexed 
to saturate FRα at the cell surface. After a rapid wash with pH 7.4 buffer, cells were exposed to 0.5 µM [3H](6S)5-
CHO-THF and tritium bound to the cell surface was assessed as a function of time. (c) The pH-dependence of 
dissociation from FRα was assessed using a strategy similar to the one described in panel b. In this case, a 1 min 
incubation with 0.5 µM [3H](6S)5-CHO-THF was employed.  One hundred percent indicates the control cells not 
exposed to unlabeled folate substrates. * indicates that pemetrexed dissociation at pH 5.0 was significantly higher 
than dissociation at pH≥6.0, but not significantly different from dissociation at pH 5.5. Data in panel a are the mean 
± S.E.M. from four independent experiments while values in panels b and c are the mean ±S.E.M. from three 
independent experiments. 
Figure 3. pH-dependent dissociation of folate substrates in the presence of 2 µM of the same substrate at 37oC.  FRα 
on the surface of R1-11-FR2 cells was first saturated with 2 µM substrate at 0oC. The cells were then exposed for 10 
min to buffers at 37oC each of which contained 2 µM of the same substrate at different pH’s. After a brief wash at 
0oC, cells were incubated with 0.5 µM [3H](6S)5-CHO-THF for 1 min at 0oC to assess the amount of unoccupied 
receptors on the cell surface. The control (100%) represents cells that were incubated with buffer only (in the 
absence of substrate) at 0oC and exposed to neutral buffer only (in the absence of substrate) at 37oC before 
incubation with [3H](6S)5-CHO-THF. Data are the mean ± S.E.M. from three independent experiments. 
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Table I. IC50 (µM) for EC0905 and antifolates in HeLa, R5, R1-11-FR2 and R5-FR12 cells 
 HeLa R5 R5-FR12G R1-11-FR2 
 Control +folic 
acid 
Control +folic 
acid 
Control +folic 
acid 
Control +folic 
acid 
One day exposure 
EC0905 0.78 
±0.26 
0.93 
±0.06 
0.62 
±0.14 
0.65 
±0.15 
0.00013 
±0.00002 
0.23 
±0.07 
0.00014 
±0.00004 
0.17 
±0.03 
ZD9331 >20 >20 >20 >20 0.90 
±0.15 
6.0 
±1.1 
>20 >20 
Raltitrexed 0.012 
±0.002 
0.010 
±0.001 
0.30 
±0.06 
0.40 
±0.06 
0.057 
±0.012 
3.3 
±0.7 
0.0057 
±0.0003 
2.8 
±0.6 
Pemetrexed 0.17 
±0.03 
0.17 
±0.03 
0.10 
±0.03 
0.10 
±0.03 
3.3 
±1.3 
7.3 
±1.3 
6.7 
±0.3 
11 
±1 
Lomotrexol 0.28 
±0.06 
0.33 
±0.06 
0.43 
±0.04 
0.57 
±0.07 
7.0 
±1.5 
8.3 
±1.0 
2.2 
±0.3 
9.7 
±1.5 
Five day exposure 
trimetrexate 0.12 
±0.02 
0.12 
±0.02 
0.012
±0.003 
0.014
±0.002 
0.42
±0.04 
0.049
±0.006 
0.042 
±0.007 
0.0052
±0.0006 
EC0905 0.25 
±0.03 
0.28 
±0.02 
0.12 
±0.02 
0.15 
±0.03 
0.00020 
±0.00003 
0.096 
±0.003 
0.00020 
±0.00003 
0.11 
±0.01 
ZD9331 0.28 
±0.06 
0.30 
±0.06 
0.87 
±0.10 
1.1 
±0.1 
0.0037 
±0.001 
1.7 
±0.3 
9.7 
±1.0 
12 
±1 
Raltitrexed 0.0057 
±0.0003 
0.0063 
±0.0003 
0.067 
±0.003 
0.15 
±0.01 
0.0083 
±0.0003 
0.70 
±0.12 
0.0024 
±0.0001 
1.7 
±0.1 
Pemetrexed 0.070 
±0.006 
0.076 
±0.012 
0.033 
±0.008 
0.043 
±0.007 
0.083 
±0.020 
0.21 
±0.05 
1.1 
±0.2 
4.3 
±0.3 
Lomotrexol 0.076 
±0.03 
0.13 
±0.01 
0.093 
±0.007 
0.40 
±0.06 
0.014 
±0.001 
1.43 
±0.19 
0.0097 
±0.0017 
7.0 
±0.6 
 
Cells were seeded in 96 well plates for one day before exposure to drugs over a spectrum of concentrations in the 
presence or absence of folic acid. For one day exposures, cells were washed once with folate-free medium after 24 
hrs and grown in folate-free medium containing 25 nM (6R,S)5-CHO-THF for an additional 4 days. For 5 day 
exposures, cells were grown in medium containing drugs continuously for 5 days. The folic acid concentration was 1 
µM for EC0905 and 200 nM when added with the other drugs.  IC50 is the concentration of drug required to reduce 
cell growth by 50%. Data are the mean ±S.E.M. from three independent experiments. 
 
 
 
 
 
 
 
 
